PL3993795T3 - Podstawiona pochodna tetrahydroizochinoliny jako pozytywny modulator allosteryczny d1 - Google Patents
Podstawiona pochodna tetrahydroizochinoliny jako pozytywny modulator allosteryczny d1Info
- Publication number
- PL3993795T3 PL3993795T3 PL20735361.6T PL20735361T PL3993795T3 PL 3993795 T3 PL3993795 T3 PL 3993795T3 PL 20735361 T PL20735361 T PL 20735361T PL 3993795 T3 PL3993795 T3 PL 3993795T3
- Authority
- PL
- Poland
- Prior art keywords
- positive allosteric
- allosteric modulator
- tetrahydroisoquinoline derivative
- substituted tetrahydroisoquinoline
- substituted
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19183641 | 2019-07-01 | ||
| PCT/EP2020/068181 WO2021001286A1 (en) | 2019-07-01 | 2020-06-29 | A substituted tetrahydroisoquinoline derivative as a d1 positive allosteric modulator |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3993795T3 true PL3993795T3 (pl) | 2026-07-20 |
Family
ID=67137842
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL20735361.6T PL3993795T3 (pl) | 2019-07-01 | 2020-06-29 | Podstawiona pochodna tetrahydroizochinoliny jako pozytywny modulator allosteryczny d1 |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US12358890B2 (pl) |
| EP (1) | EP3993795B1 (pl) |
| JP (1) | JP7618597B2 (pl) |
| KR (1) | KR102949226B1 (pl) |
| CN (1) | CN114008032B (pl) |
| AR (1) | AR119317A1 (pl) |
| AU (1) | AU2020299705B2 (pl) |
| BR (1) | BR112021022379A2 (pl) |
| CA (1) | CA3139622A1 (pl) |
| CL (1) | CL2021002949A1 (pl) |
| CO (1) | CO2021017740A2 (pl) |
| EC (1) | ECSP22007557A (pl) |
| ES (1) | ES3069145T3 (pl) |
| HR (1) | HRP20260599T1 (pl) |
| IL (1) | IL289317B2 (pl) |
| MA (1) | MA56445B1 (pl) |
| MX (1) | MX2021015872A (pl) |
| MY (1) | MY210362A (pl) |
| PE (1) | PE20220373A1 (pl) |
| PH (1) | PH12021552819A1 (pl) |
| PL (1) | PL3993795T3 (pl) |
| RS (1) | RS68243B1 (pl) |
| SA (1) | SA521431274B1 (pl) |
| SG (1) | SG11202112539XA (pl) |
| TW (1) | TWI842923B (pl) |
| UA (1) | UA130613C2 (pl) |
| WO (1) | WO2021001286A1 (pl) |
| ZA (1) | ZA202109194B (pl) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020131671A1 (en) | 2018-12-18 | 2020-06-25 | Eli Lilly And Company | Dose regimens for use of ly3154207 in the treatment of dopaminergic cns disorders |
| EP4200280B1 (en) | 2020-10-07 | 2024-02-21 | Eli Lilly And Company | Phenyl-3,4-dihydroisoquinolin-2(1h)-yl-ethan-1-one derivatives as dopamine d1 receptor positive allosteric modulators |
| CN117337173A (zh) * | 2021-03-09 | 2024-01-02 | 伊莱利利公司 | 美维达林和其他d1正向别构调节剂用于减缓帕金森氏病进展的用途 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010520217A (ja) | 2007-03-01 | 2010-06-10 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | ヒスタミンｈ３受容体のモジュレーターとしてのテトラヒドロイソキノリン化合物 |
| KR101284796B1 (ko) | 2011-10-05 | 2013-07-10 | (주)포인트엔지니어링 | 캔 패지키 타입의 광 디바이스 제조 방법 및 이에 의해 제조된 광 디바이스 |
| US9278960B2 (en) | 2011-11-03 | 2016-03-08 | Merck Sharp & Dohme Corp. | Quinoline carboxamide and quinoline carbonitrile derivatives as mGluR2-negative allosteric modulators, compositions, and their use |
| JO3316B1 (ar) | 2013-05-30 | 2019-03-13 | Lilly Co Eli | مركبات 3، 4-داي هيدرو أيزو كوينولين -2(1h)-يل |
| EA035544B1 (ru) | 2014-10-08 | 2020-07-03 | Юсб Байофарма Спрл | Производные тетрагидроизохинолина |
| CN108884050B (zh) * | 2016-04-13 | 2022-07-05 | Ucb生物制药私人有限公司 | 四氢异喹啉衍生物 |
| EP3596060B1 (en) * | 2017-03-16 | 2023-09-20 | F. Hoffmann-La Roche AG | New bicyclic compounds as atx inhibitors |
| TWI725408B (zh) | 2018-04-20 | 2021-04-21 | 美商美國禮來大藥廠 | 多巴胺d1受體正向異位調節劑 |
-
2020
- 2020-06-29 MX MX2021015872A patent/MX2021015872A/es unknown
- 2020-06-29 SG SG11202112539XA patent/SG11202112539XA/en unknown
- 2020-06-29 ES ES20735361T patent/ES3069145T3/es active Active
- 2020-06-29 CN CN202080043673.9A patent/CN114008032B/zh active Active
- 2020-06-29 PE PE2021002217A patent/PE20220373A1/es unknown
- 2020-06-29 PL PL20735361.6T patent/PL3993795T3/pl unknown
- 2020-06-29 JP JP2021575050A patent/JP7618597B2/ja active Active
- 2020-06-29 AU AU2020299705A patent/AU2020299705B2/en active Active
- 2020-06-29 RS RS20260706A patent/RS68243B1/en unknown
- 2020-06-29 US US17/621,871 patent/US12358890B2/en active Active
- 2020-06-29 MY MYPI2021006863A patent/MY210362A/en unknown
- 2020-06-29 EP EP20735361.6A patent/EP3993795B1/en active Active
- 2020-06-29 WO PCT/EP2020/068181 patent/WO2021001286A1/en not_active Ceased
- 2020-06-29 HR HRP20260599TT patent/HRP20260599T1/hr unknown
- 2020-06-29 BR BR112021022379A patent/BR112021022379A2/pt unknown
- 2020-06-29 MA MA56445A patent/MA56445B1/fr unknown
- 2020-06-29 UA UAA202106080A patent/UA130613C2/uk unknown
- 2020-06-29 IL IL289317A patent/IL289317B2/en unknown
- 2020-06-29 CA CA3139622A patent/CA3139622A1/en active Pending
- 2020-06-29 PH PH1/2021/552819A patent/PH12021552819A1/en unknown
- 2020-06-29 KR KR1020227002603A patent/KR102949226B1/ko active Active
- 2020-06-30 AR ARP200101852A patent/AR119317A1/es unknown
- 2020-06-30 TW TW109122034A patent/TWI842923B/zh active
-
2021
- 2021-11-08 CL CL2021002949A patent/CL2021002949A1/es unknown
- 2021-11-17 ZA ZA2021/09194A patent/ZA202109194B/en unknown
- 2021-12-23 CO CONC2021/0017740A patent/CO2021017740A2/es unknown
- 2021-12-30 SA SA521431274A patent/SA521431274B1/ar unknown
-
2022
- 2022-01-31 EC ECSENADI20227557A patent/ECSP22007557A/es unknown